HPLC · CoA
IGF-1 LR3 vs CJC-1295 + Ipamorelin: What Is the Difference?
Comparison · 7 min read · Updated 30 September 2026
The difference between IGF-1 LR3 vs CJC-1295 + Ipamorelin is the level of the growth hormone axis each one acts on. CJC-1295 and Ipamorelin act upstream, on the GHRH receptor and the ghrelin receptor of pituitary somatotrophs, prompting growth hormone release. IGF-1 LR3 acts downstream, binding the IGF-1 receptor on target cells directly without any pituitary involvement. The pair tests whether the pituitary can be driven to release its hormone; the 83 residue analogue bypasses that step and supplies the terminal signal itself.
How Does the Growth Hormone Axis Work?
The growth hormone axis works as a four-stage relay from the hypothalamus to target cells, with negative feedback returning from the final stage. Every comparison between these compounds depends on where they sit in that sequence.
- **Hypothalamus:** releases growth hormone releasing hormone (GHRH) and somatostatin, the stimulatory and inhibitory inputs.
- **Pituitary:** somatotroph cells release growth hormone in pulses when GHRH receptors and ghrelin receptors are activated.
- **Liver and peripheral tissues:** growth hormone acts on its own receptor and drives production of insulin-like growth factor 1 (IGF-1).
- **Target cells:** IGF-1 binds the IGF-1 receptor, a receptor tyrosine kinase that signals through PI3K and Akt, and through MAPK.
IGF-1 also acts back on the hypothalamus and pituitary to suppress further growth hormone release. That feedback loop is central to any study using compounds from both ends of the axis.
What Do CJC-1295 and Ipamorelin Do Upstream?
CJC-1295 and Ipamorelin stimulate growth hormone release from the pituitary through two separate receptors that converge on the same cells. CJC-1295 without DAC, often called Mod GRF 1-29, retains the first 29 residues of GHRH with four substitutions that slow enzymatic breakdown; its target is the GHRH receptor, where binding lifts intracellular cyclic AMP. Ipamorelin is a pentapeptide ghrelin receptor agonist, Aib, His, D-2-Nal, D-Phe, Lys, of about 712 daltons, which acts on GHS-R1a and raises intracellular calcium. Activating both receptors together produces a larger growth hormone response in models than either input alone.
We supply the pair in two formats: the CJC-1295 and Ipamorelin no DAC blend, with both peptides lyophilised together in one 10mg vial, and the GH research pair of separate vials, with independent lot numbers for studies that require adjustable ratios.
What Does IGF-1 LR3 Do Downstream?
IGF-1 LR3 activates the IGF-1 receptor directly on target cells, delivering the final signal of the axis without requiring pituitary release. Native IGF-1 is a 70 residue protein stabilised by three disulfide bridges. IGF-1 LR3 is an 83 residue analogue carrying an arginine in place of the native glutamic acid at position 3, plus an N-terminal extension of 13 residues. It has a mass of about 9,100 daltons and is produced recombinantly, then refolded so that the disulfide bridges form correctly.
Those two modifications sharply reduce binding to the six IGF binding proteins that normally sequester IGF-1 from its receptor. More of each microgram reaches the receptor and remains active for longer, which is why the analogue became a standard supplement in serum-free culture media for production cell lines such as Chinese hamster ovary cells. At high concentrations it can also activate the insulin receptor, a cross-reactivity that should be controlled for in metabolic cell work.
IGF-1 LR3 vs CJC-1295 + Ipamorelin at a Glance
| Feature | IGF-1 LR3 | CJC-1295 + Ipamorelin |
|---|---|---|
| Level of the axis | target cell (downstream) | pituitary (upstream) |
| Receptors | IGF-1 receptor, some insulin receptor at high levels | GHRH receptor and GHS-R1a |
| Size | 83 residues, about 9,100 Da | 29 residues (about 3,368 Da) plus 5 residues (about 712 Da) |
| Manufacture | recombinant, refolded | solid-phase synthesis |
| Requires an intact pituitary | no | yes |
| Typical models | cell culture, bioprocessing, receptor signalling | pituitary cells, animal models of GH pulsatility |
| Primary readouts | receptor phosphorylation, Akt and MAPK activity, cell growth | growth hormone release, then IGF-1 |
| Vial sizes we stock | 0.1mg and 1mg | 10mg blend, or separate vials in the pair |
The difference in vial size reflects potency. IGF-1 LR3 is active at nanogram per millilitre concentrations in culture, so a 1mg vial serves many experiments, while the pituitary peptides are handled in milligram quantities.
Can IGF-1 LR3 and CJC-1295 + Ipamorelin Be Combined in One Study?
IGF-1 LR3 and CJC-1295 + Ipamorelin can be combined in one study as a multi-arm design, which is the correct way to frame the IGF-1 LR3 CJC-1295 + Ipamorelin stack in research. Running the upstream pair alongside the downstream analogue separates effects that depend on pituitary release from effects that depend only on IGF-1 receptor activation. Three design points require attention.
- **Feedback:** exogenous IGF-1 activity suppresses growth hormone release, so the upstream signal may diminish when both are present. Measure growth hormone and IGF-1 separately.
- **Assay interference:** IGF-1 immunoassays may or may not cross-react with the LR3 analogue. Validate the assay before reading IGF-1 levels in a combined arm.
- **Controls:** each compound needs its own arm, plus a vehicle control, or the combined result cannot be attributed to either.
For in-vitro work, the pituitary peptides are meaningful only in pituitary cell models, while IGF-1 LR3 acts on almost any cell line expressing its receptor. That constraint usually settles the design first.
How Is the CJC-1295 and Ipamorelin 10mg Blend Reconstituted and Stored?
The 10mg blend is reconstituted with bacteriostatic water released slowly down the vial wall and swirled until clear, then kept refrigerated between 2 and 8 degrees C for up to 28 days. The table gives combined peptide content; the split between the two compounds follows the amounts printed on the label and certificate.
| Vial | Diluent | Combined concentration | Combined peptide in 10 units (0.1 mL) |
|---|---|---|---|
| Blend, 10 mg | 2 mL | 5 mg/mL combined | 500 mcg combined |
| Blend, 10 mg | 3 mL | 3.33 mg/mL combined | 333 mcg combined |
| IGF-1 LR3, 1 mg | 1 mL | 1,000 mcg/mL | 100 mcg |
| IGF-1 LR3, 0.1 mg | 1 mL | 100 mcg/mL | 10 mcg |
IGF-1 LR3 is normally dissolved in dilute acid rather than water, following the certificate, and our research-grade acetic acid is stocked for that purpose. At low concentrations the protein adsorbs to plastic, so culture laboratories often add a carrier protein. Sealed vials of all three products are held at minus 20 degrees C. The reconstituted blend is refrigerated and used within 28 days, while IGF-1 LR3 is divided into single-use aliquots and frozen to avoid repeated thawing. The standard diluent for the blend is our 3 mL or 10 mL bacteriostatic water.
Which Compound Fits Which Study?
The compound should be chosen by the level of the axis the hypothesis addresses, not by relative potency. The main study types map as follows.
- Pituitary pulsatility, GHRH and ghrelin receptor synergy, or secretagogue selectivity: the CJC-1295 and Ipamorelin pair.
- IGF-1 receptor signalling, cell growth in culture or serum-free media: IGF-1 LR3.
- Separating pituitary-dependent from receptor-direct effects: both, in a fully controlled multi-arm design.
Our recommendation: define the level of the axis first, then select the compound. The remainder of our growth hormone research peptides covers the other GHRH and ghrelin receptor tools, and every lot is released with an HPLC result of 98% or higher and its own certificate of analysis.
Questions about IGF-1 LR3 vs CJC-1295 + Ipamorelin
Sources
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.